Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard A Larson

Showing results (291-300 of 384) with videos related to

Pageof 39
Sort By:
Acta Haematologica|September 16, 2016
Telomere Length Recovery: A Strong Predictor of Overall Survival in Acute Promyelocytic LeukemiaMuhamed Baljevic, Bogdan Dumitriu, Ju-Whei Lee, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 4, 2008
Distinct microRNA expression profiles in acute myeloid leukemia with common translocationsZejuan Li, Jun Lu, Miao Sun, et al.
Transplantation and Cellular Therapy|December 16, 2022
Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage ChemotherapyAlexander E Perl, Richard A Larson, Nikolai A Podoltsev, et al.
Blood|February 26, 2025
Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 studyJoshua F Zeidner, David A Sallman, Christian Récher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 9, 2005
Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B studyGuido Marcucci, Claudia D Baldus, Amy S Ruppert, et al.
Blood Neoplasia|June 2, 2025
Devimistat plus chemotherapy vs chemotherapy alone for older relapsed or refractory patients with AML: results of the ARMADA trialTimothy S Pardee, Bayard L Powell, Richard A Larson, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 26, 2019
Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular TherapyZachariah DeFilipp, Anjali S Advani, Veronika Bachanova, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2010
IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studyGuido Marcucci, Kati Maharry, Yue-Zhong Wu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 2010
Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studySebastian Schwind, Kati Maharry, Michael D Radmacher, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 8, 2012
MiR-495 is a tumor-suppressor microRNA down-regulated in MLL-rearranged leukemiaXi Jiang, Hao Huang, Zejuan Li, et al.
Pageof 39

Showing results (291-300 of 384) with videos related to

Sort By:
Pageof 39
Acta Haematologica|September 16, 2016
Telomere Length Recovery: A Strong Predictor of Overall Survival in Acute Promyelocytic LeukemiaMuhamed Baljevic, Bogdan Dumitriu, Ju-Whei Lee, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 4, 2008
Distinct microRNA expression profiles in acute myeloid leukemia with common translocationsZejuan Li, Jun Lu, Miao Sun, et al.
Transplantation and Cellular Therapy|December 16, 2022
Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage ChemotherapyAlexander E Perl, Richard A Larson, Nikolai A Podoltsev, et al.
Blood|February 26, 2025
Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 studyJoshua F Zeidner, David A Sallman, Christian Récher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 9, 2005
Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B studyGuido Marcucci, Claudia D Baldus, Amy S Ruppert, et al.
Blood Neoplasia|June 2, 2025
Devimistat plus chemotherapy vs chemotherapy alone for older relapsed or refractory patients with AML: results of the ARMADA trialTimothy S Pardee, Bayard L Powell, Richard A Larson, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 26, 2019
Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular TherapyZachariah DeFilipp, Anjali S Advani, Veronika Bachanova, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2010
IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studyGuido Marcucci, Kati Maharry, Yue-Zhong Wu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 2010
Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studySebastian Schwind, Kati Maharry, Michael D Radmacher, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 8, 2012
MiR-495 is a tumor-suppressor microRNA down-regulated in MLL-rearranged leukemiaXi Jiang, Hao Huang, Zejuan Li, et al.
Pageof 39